

Semaglutide, 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg FlexTouch solution for injection in pre-filled pen (Wegovy®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2497	<p>As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of:</p> <ul style="list-style-type: none"> • $\geq 30\text{kg/m}^2$ (obesity), or • $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity. <p>SMC restriction: BMI of $\geq 30\text{kg/m}^2$* in the presence of at least one weight-related comorbidity. Patients should be treated in a specialist weight management service.</p> <p>*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024

Other Decision Specified :

Web Link : <https://www.scottishmedicines.org.uk/medicines-advice/semaglutide-wegovy-full-smc2497/>

Lutetium (177Lu) vipivotide tetraxetan solution for injection or infusion (Pluvicto®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2517	Treatment of adult patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.	Not routinely available as not recommended for use in NHS Scotland	18/10/2023	18/10/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/lutetium-177lu-vipivotide-tetraxetan-pluvicto-full-smc2517/				
Olaparib film-coated tablets (Lynparza®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2518	As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have human epidermal growth factor receptor 2 (HER2)-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2518/				

Brexucabtagene autoleucel 0.4 – 2 × 10⁸ cells dispersion for infusion (Tecartus®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2548	Treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).	Available in line with national guidance	18/10/2023	18/10/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/brexucabtagene-autoleucel-tecartus-full-smc2548/				
Regorafenib film-coated tablets (Stivarga®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2562	As monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/regorafenib-stivarga-full-smc2562/				

Fenfluramine oral solution (Fintepla®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2569	For the treatment of seizures associated with Dravet syndrome as an add-on to other anti-epileptic medicines for patients 2 years of age and older.	Available in line with national guidance	18/10/2023	18/10/2023
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/fenfluramine-fintepla-full-smc2569/				
Voclosporin soft capsule (Lupkynis®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2570	In combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis.	Not routinely available as there is a local preference for alternative medicines	18/10/2023	17/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/voclosporin-lupkynis-full-smc2570/				

Maribavir film-coated tablets (Livtency®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2576	Treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.	Not routinely available as there is a local preference for alternative medicines	18/10/2023	17/01/2024
Other Decision Specified : No response from haematology, decision updated January 2024				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/maribavir-livtency-full-smc2576/				
Belzutifan film-coated tablets (Welireg®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2587	Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/belzutifan-welireg-full-smc2587/				

Atogepant tablets (Aquipta®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2599	For the prophylaxis of migraine in adults who have at least 4 migraine days per month. SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/atogepant-aquipta-abbreviated-smc2599/				
Zanubrutinib 80 mg hard capsules (Brukinsa®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2600	As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). SMC restriction: For adults with CLL in whom chemo-immunotherapy is unsuitable.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/zanubrutinib-brukinsa-abbreviated-smc2600/				

Darolutamide 300mg film-coated tablets (Nubeqa®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2604	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2023	31/01/2024
Other Decision Specified :				
Web Link : https://www.scottishmedicines.org.uk/medicines-advice/darolutamide-nubeqa-ft-resub-smc2604/				